'Going Viral: The Inside Story of Covaxin', written by ICMR DG Dr Balram Bhargava, was handed over to WHO and UN officials by the author during an event at UNAIDS office in Geneva.
The proposed trial can be on people who either have not been vaccinated or who already received two doses of an mRNA vaccine at least six months earlier in the US.
WHO official Dr Margaret Harris said the technical advisory group that reviews all the data for a potential emergency use listing is studying Covaxin today (26 October).
Long wait for Covaxin’s emergency-use listing has perplexed many. The issue was discussed at great length during Health Minister Mansukh Mandaviya’s meeting with WHO Director-General Tuesday.
During a call, WHO chief Tedros Adhanom Ghebreyesus and Health Minister Mansukh Mandaviya also discussed the resumption of supply of Covishield to COVAX facility.
Bharat Biotech had last month said it has submitted all data pertaining to Covaxin to the WHO for emergency use and is awaiting feedback from the global health watchdog.
Currently, three vaccines — Covishield, Covaxin and Sputnik V — being administered in the country are only for those above 18 years of age. All of them are two-dose vaccines.
Data shows re-alignment in India’s exports, with Tamil Nadu & Telangana posting strong growth in 2024-25 as traditional heavyweights Gujarat & Maharashtra see declines. Gujarat still leads, though.
Of the total package, $649 million will be utilised for additional hardware, software, and support services, and the remaining for Major Defence Equipment (MDE).
Don’t blame misfortune. This is colossal incompetence and insensitivity. So bad, heads would have rolled even in the old PSU-era Indian Airlines and Air India.
COMMENTS